Drouin-Ouellet Janelle
Neurodegener Dis Manag. 2014;4(4):297-307. doi: 10.2217/nmt.14.26.
Cell-based therapies for Parkinson's and Huntington's disease have provided mixed clinical outcomes and one of the reasons underlying this is the use of primary fetal tissue as the source of grafted cells. An alternate source of cells, such as stem cells, could overcome many of the issues associated with primary fetal tissue and would help bring forward cell replacement therapy as a reliable and effective treatment for these two neurodegenerative disorders. This review will discuss which stem cells are likely to go to clinic in the next generation of cells, based on trials for Parkinson's and Huntington's disease.
用于帕金森病和亨廷顿病的细胞疗法临床结果不一，其背后的原因之一是使用原代胎儿组织作为移植细胞的来源。细胞的替代来源，如干细胞，可克服与原代胎儿组织相关的许多问题，并有助于推动细胞替代疗法成为这两种神经退行性疾病可靠而有效的治疗方法。基于帕金森病和亨廷顿病的试验，本综述将讨论下一代细胞中哪些干细胞可能会进入临床应用。
